Oxaliplatin
Product Images NDC 0955-1733

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 0955-1733). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Oxaliplatin Premier 01)

Chemical structure of oxaliplatin showing the platinum atom centrally bonded to a 1,2-diaminocyclohexane ligand and an oxalate group.*

FDA Label Image

Chemical Structure (Oxaliplatin Premier 02)

A Kaplan-Meier curve comparing disease-free survival (DFS) probability over months between two treatment arms, FOLFOX4 and LV5FU2. The solid line represents FOLFOX4 with fewer events (27.1%) compared to the dashed line LV5FU2 (32.1%). The graph includes hazard ratio, confidence interval, p-value, and numbers of patients at risk over time.*

FDA Label Image

Figure 2 (Oxaliplatin Premier 03)

A Kaplan-Meier survival curve chart showing disease-free survival (DFS) probability over time (months) for two treatment arms: FOLFOX4 versus LV5FU2 in the DUKES C group. The graph includes a hazard ratio (0.78) with 95% confidence interval [0.65, 0.93] and a p-value (0.005) from a logrank test, comparing outcomes in Stage III patients.*

FDA Label Image

Figure 3 (Oxaliplatin Premier 04)

A survival curve chart showing the percentage of patients surviving over 24 months, comparing three treatment regimens: ELOXATIN plus 5-FU/LV, ELOXATIN plus irinotecan, and irinotecan plus 5-FU/LV. Median survival times are 19.4, 17.6, and 14.6 months respectively, with statistical significance noted (p<0.0001).*

FDA Label Image

Figure 4 (Oxaliplatin Premier 05)

OXALIPLATIN injection 50 mg / 10 mL (5 mg/mL) single-dose vial packaging label. The label includes warnings for cytotoxic agent use and instructions against mixing with sodium chloride/chloride-containing solutions. Manufactured by Sanofi-Aventis U.S. LLC, the label displays dosage form, manufacturer details, storage instructions, and a barcode. The product is for intravenous infusion after dilution.*

FDA Label Image

Principal Display Panel (10 mL Vial Carton)

The packaging label for Oxaliplatin injection 100 mg/20 mL (5 mg/mL) by Sanofi-Aventis U.S. LLC features dosing and storage information. It highlights the drug as a cytotoxic agent for intravenous infusion after dilution, warns against mixing with sodium chloride or chloride-containing solutions, and provides manufacturer details and barcode on the box.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.